Titan Investment Solutions Ltd bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 86,905 shares of the medical research company’s stock, valued at approximately $7,409,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Washington Trust Advisors Inc. grew its stake in shares of Edwards Lifesciences by 15.6% during the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after buying an additional 17,625 shares during the period. Elo Mutual Pension Insurance Co grew its stake in shares of Edwards Lifesciences by 39.9% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after buying an additional 25,562 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Edwards Lifesciences by 39.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after buying an additional 648,870 shares during the period. Finally, Central Pacific Bank Trust Division purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $775,000. 79.46% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Edwards Lifesciences
In related news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 81,038 shares of company stock valued at $6,683,255 in the last quarter. Company insiders own 0.31% of the company’s stock.
Edwards Lifesciences Stock Down 0.9%
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the company earned $0.64 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on EW shares. Barclays reissued an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Evercore reissued an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Finally, Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.
Read Our Latest Stock Report on Edwards Lifesciences
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
- Five stocks we like better than Edwards Lifesciences
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
